Clinical Trials Browser

Biliary Tract Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Urologic Neoplasms, Uterine Neoplasms, Colorectal Neoplasms

NCT05583110 2025-12-10

TrasTUCAN

Phase 2 Terminated

13 enrolled

Breast

Breast Neoplasms

NCT04538742 2025-12-08

DB-07

Phase 1/2 Active not recruiting

245 enrolled

BreastCNS

Brain Neoplasms, Breast Neoplasms

NCT05800275 2025-11-18

ETIC-LM

Phase 2 Recruiting

30 enrolled

CNS

Meningeal Neoplasms, Meningeal Carcinomatosis

NCT05041842 2025-11-17

InTTercePT

Phase 2 Active not recruiting

53 enrolled

Breast

Metastatic Breast Cancer With a Isolated Brain Progression

NCT04457596 2025-10-29

T-DM1 and Tucatinib Compared With T-DM1 Alone in Preventing Relapses in People With High Risk HER2-Positive Breast Cancer, the CompassHER2 RD Trial

Phase 3 Active not recruiting

1,056 enrolled

Breast

Anatomic Stage IA Breast Cancer AJCC v8

NCT06239467 2025-09-09

PIKture-01

Phase 1 Recruiting

200 enrolled

Breast

Breast Neoplasms

NCT03501979 2025-08-29

Tucatinib, Trastuzumab, and Capecitabine for the Treatment of HER2+ LMD

Phase 2 Terminated

17 enrolled 16 charts

Breast

Breast Neoplasms, Meningeal Neoplasms

NCT06439693 2025-06-26

The SAPPHO Study: Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast Cancer

Phase 2 Recruiting

72 enrolled

Breast

Breast Neoplasms

NCT04789096 2025-06-06

TUGETHER

Phase 2 Terminated

31 enrolled

Breast

Breast Neoplasms

NCT05319873 2025-05-13

Ribociclib, Tucatinib, and Trastuzumab for the Treatment of HER2 Positive Breast Cancer

Phase 1/2 Recruiting

18 enrolled

Breast

Anatomic Stage II Breast Cancer AJCC v8

NCT05868226 2025-04-04

PRE-I-SPY-PI

Phase 1 Recruiting

124 enrolled

Breast

Breast Neoplasms, Neoplasm Metastasis, Triple Negative Breast Neoplasms

NCT05955170 2025-03-27

TUC-TOC

Phase 2 Recruiting

66 enrolled

Breast

HER2-positive Breast Cancer

NCT04499924 2025-01-22

MOUNTAINEER-02

Phase 2/3 Completed

17 enrolled 23 charts

Gastrointestinal

Adenocarcinoma Of Esophagus

NCT04632992 2025-01-08

MyTACTIC

Phase 2 Completed

252 enrolled 27 charts

Advanced Unresectable or Metastatic Solid Malignancy

NCT02892123 2024-11-27

Trial of ZW25 (Zanidatamab) in Patients With Advanced HER2-expressing Cancers

Phase 1 Completed

279 enrolled

BreastGastrointestinalGynecologicThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Neoplasms, Ovarian Neoplasms, Stomach Neoplasms

NCT03043313 2024-11-26

Tucatinib Plus Trastuzumab in Patients With HER2+ Colorectal Cancer

Phase 2 Completed

117 enrolled 21 charts 2 FDA

Gastrointestinal

Colorectal Neoplasms

NCT05356897 2024-09-19

Tucatinib Combined with Trastuzumab and TAS-102 for the Treatment of HER2 Positive Metastatic Colorectal Cancer in Molecularly Selected Patients, 3T Study

Phase 2 Withdrawn

Gastrointestinal

Colonic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms

NCT06162559 2024-01-11

TRAIN-4

Phase 1 Recruiting

30 enrolled

Breast

Breast Neoplasms

NCT03054363 2023-11-13

Tucatinib, Palbociclib and Letrozole in Metastatic Hormone Receptor Positive and HER2-positive Breast Cancer

Phase 1/2 Completed

42 enrolled 16 charts

Breast

Breast Neoplasms

NCT06067776 2023-10-05

Osimertinib, Cetuximab, and Tucatinib for the Treatment of EGFR-Mutant Stage IV or Recurrent Non-small Lung Cell Cancer

Phase 1 Not yet recruiting

36 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT02614794 2023-08-14

HER2CLIMB

Phase 2 Completed

612 enrolled 30 charts 3 FDA

BreastCNS

Brain Neoplasms, Breast Neoplasms

NCT04896320 2023-06-22

2019-101826

Phase 1/2 Withdrawn

Breast

Breast Neoplasms, Neoplasm Metastasis

NCT05190445 2022-09-08

Cinrebafusp Alfa in Combination With Ramucirumab and Paclitaxel in HER2-High Gastric or GEJ Adenocarcinoma and in Combination With Tucatinib in HER2-Low Gastric or GEJ Andenocarinoma

Phase 2 Active not recruiting

80 enrolled

Gastrointestinal

HER2-positive Gastric Cancer

Clinical Trials

BREnnA

HER2CLIMB-05

MOUNTAINEER-03

Tucatinib+Trastuzumab+Eribulin in HER2+ MBC

TAPUR

A Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer

CAPTUR

JAZMINE

HER2CLIMB-04

Study of Tucatinib and Doxil in Participants With Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Metastatic Breast Cancer

BRIDGET

A Study of Disitamab Vedotin With Other Anticancer Drugs in Solid Tumors

Clinical Trial of Alpelisb and Tucatinib in Patients With PIK3CA-Mutant HER2+ Metastatic Breast Cancer.

I-SPY

Safety and Pharmacokinetics of Tucatinib (MK-7119) in Chinese Participants With Cancer (MK-7119-002)

A Study of Tucatinib and Trastuzumab in People With Rectal Cancer

ASCEND-CRC: Profiling and Targeting Dynamic Tumor Resistance in Patients With Metastatic Colorectal Cancer

Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER2+ Gastrointestinal Cancers

Tucatinib, Trastuzumab and Capecitabine With Brain and/or Spinal Radiotherapy (XRT) in Patients With HER2+, HER2 Mutated and/or HER2-amplified Metastatic Breast Cancer and Leptomeningeal Disease: A Multi-centre Phase II, Single Arm Feasibility Study

H3RAKLES

A Study of Tucatinib Given Before Surgery to People With HER2+ Cancers That Have Spread to the Brain

MK-1022-009

ERASE-CRC

A Phase II Study of Tucatinib and Ado-trastuzumab Emtansine (T-DM1) in Patients With HER2-positive Metastatic Solid Tumors and Metastases to Brain (TUCATEMEB)

MK-7119-001

Tucatinib, Trastuzumab, and Capecitabine With SRS for Brain Metastases From HER-2 Positive Breast Cancer

Basket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 Alterations

TrasTUCAN

DB-07

ETIC-LM

InTTercePT

T-DM1 and Tucatinib Compared With T-DM1 Alone in Preventing Relapses in People With High Risk HER2-Positive Breast Cancer, the CompassHER2 RD Trial

PIKture-01

Tucatinib, Trastuzumab, and Capecitabine for the Treatment of HER2+ LMD

The SAPPHO Study: Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast Cancer

TUGETHER

Ribociclib, Tucatinib, and Trastuzumab for the Treatment of HER2 Positive Breast Cancer

PRE-I-SPY-PI

TUC-TOC

MOUNTAINEER-02

MyTACTIC

Trial of ZW25 (Zanidatamab) in Patients With Advanced HER2-expressing Cancers

Tucatinib Plus Trastuzumab in Patients With HER2+ Colorectal Cancer

Tucatinib Combined with Trastuzumab and TAS-102 for the Treatment of HER2 Positive Metastatic Colorectal Cancer in Molecularly Selected Patients, 3T Study

TRAIN-4

Tucatinib, Palbociclib and Letrozole in Metastatic Hormone Receptor Positive and HER2-positive Breast Cancer

Osimertinib, Cetuximab, and Tucatinib for the Treatment of EGFR-Mutant Stage IV or Recurrent Non-small Lung Cell Cancer

HER2CLIMB

2019-101826

Cinrebafusp Alfa in Combination With Ramucirumab and Paclitaxel in HER2-High Gastric or GEJ Adenocarcinoma and in Combination With Tucatinib in HER2-Low Gastric or GEJ Andenocarinoma